February 28, 2014 | Venture Capitalists believe that the best way to reduce drug-development costs is redesigned clinical trials. Fewer patients, conditional approval of drugs, and required postmarket surveillance would have a profound effect, say the authors of a New England Journal of Medicine perspective piece. New England Journal of Medicine